Physician profile
Mark Chua
NPI 1659819563
$14,836.57
in general payments reported to CMS, 2019-2025
37 companies · $1,338 in 2025
The $1,338 reported for 2025 was more than what 91% of Family providers received nationally (typical 2025 total: $167).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2021: $3,829 · 2022: $4,351 · 2023: $3,801 · 2024: $1,517 · 2025: $1,338.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $6,657.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $6,656.68 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Novo Nordisk INC | $2,327.50 | 2021-2025 | Ozempic, Rybelsus, Wegovy |
| Astrazeneca Pharmaceuticals LP | $1,909.44 | 2021-2025 | Breztri, Farxiga, Airsupra |
| Abbvie INC. | $1,842.97 | 2021-2024 | |
| Glaxosmithkline, LLC. | $1,197.01 | 2021-2025 | Trelegy Ellipta, Arexvy, Shingrix |
| Lilly USA, LLC | $983.45 | 2021-2025 | Mounjaro, Jardiance, Zepbound |
| Bayer Healthcare Pharmaceuticals INC. | $766.03 | 2021-2025 | |
| Boehringer Ingelheim Pharmaceuticals, INC. | $558.83 | 2021-2023 | Jardiance, Tradjenta |
| Sanofi-Aventis U.S. LLC | $458.28 | 2021-2022 | |
| Takeda Pharmaceuticals U.S.A., INC. | $396.51 | 2021-2023 | Trintellix |
| Otsuka America Pharmaceutical, INC. | $367.20 | 2022-2024 | Rexulti |
| Amgen INC. | $365.57 | 2021-2025 | Repatha, Otezla, Otezla |
| Pfizer INC. | $355.40 | 2021-2025 | |
| Astellas Pharma US INC | $353.58 | 2021-2024 | Veozah |
| Biohaven Pharmaceutical Holding Company LTD. | $351.63 | 2022 | |
| Merck Sharp & Dohme LLC | $295.60 | 2021-2023 | Verquvo, Belsomra, Steglatro |
Show all 37 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Abbott Laboratories | $286.66 | 2021-2024 | Freestyle Libre 3, Freestyle Libre 2 |
| Axsome Therapeutics, INC. | $264.58 | 2024-2025 | Auvelity |
| Dexcom, INC. | $247.15 | 2021-2023 | Dexcom G6 Transmitter |
| Novartis Pharmaceuticals Corporation | $213.02 | 2021-2023 | |
| Salix Pharmaceuticals, A Division of Bausch Health US, LLC | $189.45 | 2021-2023 | Xifaxan, Trulance |
| E.R. Squibb & Sons, L.L.C. | $180.14 | 2021-2023 | Eliquis |
| Phathom Pharmaceuticals, INC. | $131.88 | 2025 | Voquezna |
| Medtronic, INC. | $126.14 | 2022 | |
| Biohaven Pharmaceuticals, INC. | $124.64 | 2021 | |
| Idorsia Pharmaceuticals US INC | $96.18 | 2023 | Quviviq |
| Exact Sciences Corporation | $76.47 | 2023-2025 | Cologuard Collection Kit |
| Amarin Pharma, INC. | $65.70 | 2021-2022 | |
| Lundbeck LLC | $55.05 | 2022-2024 | Rexulti |
| Kowa Pharmaceuticals America, INC. | $49.93 | 2021-2022 | |
| Xeris Pharmaceuticals, INC. | $47.60 | 2022-2023 | Gvoke Hypopen |
| Eisai INC. | $45.08 | 2021-2022 | |
| Mylan Specialty L.P. | $31.61 | 2022-2023 | Yupelri |
| Bausch Health US, LLC | $22.72 | 2022 | |
| Genentech USA, INC. | $16.21 | 2021 | |
| Janssen Pharmaceuticals, INC | $13.90 | 2023 | Xarelto |
| Hikma Pharmaceuticals USA | $11.73 | 2021 | |
| Eyevance Pharmaceuticals LLC | $11.73 | 2021 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Mark Chua listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.